RVax-1 Attenuated Vaccine Segment Modification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current RVF vaccines face challenges in providing effective and safe immunization against Rift Valley fever virus, particularly due to concerns about reassortant formation and safety profiles across different animal species and ages, with existing vaccines requiring multiple doses and showing variable immunogenicity and adverse effects.
Innovation Solution
Development of a third-generation MP-12 vaccine, RVax-1, which incorporates attenuated L, M, and S segments with modified 78-kD/NSm gene expression, designed to enhance safety and immunogenicity, reduce reassortant formation, and be traceable, utilizing reverse genetics to create a vaccine suitable for human use in endemic areas.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If live-attenuated MP-12 vaccine is used, then strong immunogenicity is achieved, but safety concerns arise due to reassortant formation and adverse effects in different animal species
Solution Approach 1:
The vaccine genome is divided into three separate segments (L, M, and S segments) that can be independently manipulated. The M segment is further segmented to include or exclude specific genes (NSm and 78-kD) depending on the desired vaccine strain, allowing precise control over immunogenicity and safety properties
Solution Approach 2:
Different regions of the viral genome are modified with different qualities: the L segment contains 326 silent mutations for attenuation, the M segment has variable gene content (with or without NSm/78-kD) to control pathogenicity, and the S segment contains 73 silent mutations. This localized modification approach allows simultaneous optimization of multiple vaccine properties
2Object-affected harmful factors
If formalin-inactivated TSI-GSD-200 vaccine is used, then safety is improved, but immunogenicity is weak and multiple doses are required
Solution Approach 1:
The vaccine transitions from an inactivated state (TSI-GSD-200) to a live-attenuated state (RVax-1) by introducing specific genetic modifications. The parameter change involves adding 566 silent mutations and modifying gene expression levels, which transforms the virus from non-infectious to attenuated but immunogenic, achieving both safety and strong immune response
3Reliability
If MP-12 vaccine is used in pregnant animals, then immunogenicity is achieved, but fetal malformations occur
Solution Approach 1:
The NSm and 78-kD genes are extracted (removed) from the M segment of the vaccine strain used in pregnant animals. This extraction eliminates the harmful effects on fetal development while preserving the essential immunogenicity of the vaccine through the remaining viral components
4Productivity
If single-dose vaccination is implemented, then productivity is improved, but achieving adequate immunity becomes more difficult
Solution Approach 1:
The vaccine is pre-modified with multiple attenuating mutations and optimized gene expression levels before administration. This preliminary genetic engineering ensures that a single dose contains all necessary elements for adequate immune response, eliminating the need for multiple booster shots
Data Source
AI summary
Certain embodiments are directed to an improved RVF vaccine for human use, and method for producing the same.